Insomnia Disorder: CBT-I First-Line, Pharmacotherapy Hierarchy, and DORA Selection
Executive Summary
Insomnia disorder per DSM-5-TR requires dissatisfaction with sleep quantity/quality (initial, middle, or terminal insomnia), occurring ≥3 nights/week for ≥3 months, with daytime impairment and despite adequate opportunity for sleep. Cognitive behavioral therapy for insomnia (CBT-I) is the universal first-line treatment per AASM, ACP, and EAU guidelines — components include sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relaxation. When pharmacotherapy is needed, the modern hierarchy favors dual orexin receptor antagonists (DORAs) — suvorexant, lemborexant, daridorexant — over Z-drugs (zolpidem, eszopiclone) due to lower dependence, less rebound insomnia, and physiologic sleep architecture preservation. Daridorexant 50 mg HS, lemborexant 5–10 mg HS, and suvorexant 10–20 mg HS are FDA-approved first-line pharmacologic options. Avoid chronic benzodiazepines and over-the-counter diphenhydramine in older adults. Always taper hypnotics gradually after CBT-I has consolidated.
1. Pathophysiology & DSM-5-TR Criteria
Pathophysiology — the hyperarousal model
Insomnia is increasingly understood as a disorder of hyperarousal — physiologic, cognitive, and emotional. The two-process model of sleep regulation describes (1) a homeostatic sleep drive (process S) that accumulates with wakefulness and dissipates during sleep, and (2) a circadian process (C) governed by the suprachiasmatic nucleus. In insomnia, the wake-promoting systems remain pathologically active during sleep periods. Implicated systems:
- HPA axis hyperactivity — elevated evening cortisol, blunted nocturnal cortisol nadir.
- Sympathetic dominance — increased nocturnal heart rate, reduced heart rate variability, elevated body temperature.
- Cortical hyperarousal — increased high-frequency EEG (beta and gamma) activity during NREM sleep; the “tired but wired” phenotype.
- Orexin/hypocretin overdrive — orexin neurons in the lateral hypothalamus stabilize wakefulness; persistent activity during the sleep period contributes to insomnia.
- Cognitive arousal — pre-sleep worry, sleep-effort paradox (trying harder to sleep worsens it), maladaptive sleep beliefs.
DSM-5-TR diagnostic criteria for insomnia disorder
| Criterion | Description |
|---|---|
| A. Predominant complaint | Dissatisfaction with sleep quantity or quality, with one or more: (1) difficulty initiating sleep, (2) difficulty maintaining sleep with frequent awakenings, (3) early-morning awakening with inability to return to sleep |
| B. Daytime impairment | Causes clinically significant distress or impairment in social, occupational, educational, academic, behavioral, or other important areas |
| C. Frequency | Sleep difficulty occurs ≥3 nights per week |
| D. Duration | Sleep difficulty present for ≥3 months |
| E. Adequate opportunity | Difficulty occurs despite adequate opportunity for sleep |
| F. Not better explained | Not better explained by another sleep-wake disorder (e.g., narcolepsy, OSA, RLS, circadian rhythm disorder) |
| G. Not solely due to substance | Not attributable to physiologic effects of a substance (e.g., drug of abuse, medication) |
| H. Not coexisting condition | Coexisting mental and medical disorders do not adequately explain the predominant complaint of insomnia |
Specifiers: with mental comorbidity, with medical comorbidity, with another sleep disorder; episodic (1–3 mo), persistent (≥3 mo), recurrent (≥2 episodes within 1 year). Short-term insomnia <3 months is coded separately as “Other Specified Insomnia Disorder.”
2. Assessment, Sleep Diary & Differential Diagnosis
History essentials
- Sleep latency (time from lights out to sleep onset; typically <30 min).
- Wake after sleep onset (WASO) (cumulative awake time during the night; typically <30 min in adults).
- Total sleep time, time in bed, sleep efficiency (TST/TIB; normal >85%).
- Bed/rise time consistency, weekend vs weekday pattern.
- Daytime symptoms — fatigue, sleepiness, impaired attention/memory, mood changes, motor coordination, motivation deficits.
- Substance/medication exposure — caffeine timing/dose, alcohol (which fragments sleep architecture even at low doses), nicotine, illicit drugs, prescribed stimulants, beta-blockers, decongestants, theophylline, glucocorticoids, OCPs, SSRIs, methylphenidate.
- Comorbid conditions — depression, anxiety, PTSD, chronic pain, GERD, BPH, congestive heart failure, COPD, RLS, OSA risk factors.
Sleep diary & objective tools
A 1–2 week sleep diary completed prospectively is the cornerstone clinical assessment tool. Validated questionnaires include the Insomnia Severity Index (ISI) (7 items, 0–28; ≥15 = clinically significant insomnia) and the Pittsburgh Sleep Quality Index (PSQI) (19 items, >5 indicates poor sleep). Actigraphy (wrist-worn motion sensors) provides 1–2 weeks of objective sleep estimates and is helpful when self-report is inconsistent with clinical impression.
Polysomnography (PSG) is NOT routinely indicated for insomnia disorder. Reserve PSG for: suspected obstructive sleep apnea, periodic limb movement disorder, REM behavior disorder, narcolepsy, parasomnias, treatment-refractory insomnia, or insomnia with excessive daytime sleepiness disproportionate to sleep restriction.
Differential diagnosis
| Differential | Distinguishing features |
|---|---|
| Obstructive sleep apnea (OSA) | Snoring, witnessed apneas, morning headaches, EDS, BMI elevation, neck circumference; STOP-BANG screen — proceed to PSG |
| Restless legs syndrome (RLS) | Urge to move legs at rest, worse evening/night, relieved by movement; iron studies (ferritin <75 ng/mL associated) |
| Circadian rhythm sleep-wake disorders | Delayed sleep-phase, advanced sleep-phase, shift work, jet lag — sleep is normal in quality but mistimed |
| Mood / anxiety disorder | Depression often presents with terminal insomnia and anhedonia; anxiety with initial insomnia; bidirectional with insomnia disorder |
| Chronic pain syndromes | Pain-induced fragmentation; treat the pain; analgesic-related insomnia (NSAIDs benign; opioids fragment) |
| Substance-induced | Caffeine, alcohol withdrawal, stimulants, glucocorticoids, beta-blockers |
| REM sleep behavior disorder (RBD) | Dream enactment, vocalizations; α-synucleinopathy prodrome — refer to sleep medicine for PSG |
| Hypothyroidism, hyperthyroidism | Hyperthyroid causes insomnia; check TSH if clinical suspicion |
3. CBT-I: First-Line Treatment
The American Academy of Sleep Medicine, American College of Physicians (2016), European Sleep Research Society (2017), and 2024 international consensus all recommend CBT-I as first-line treatment for chronic insomnia disorder — superior to all pharmacotherapies in long-term effectiveness, with response rates of 70–80% and durable benefit beyond treatment cessation. CBT-I is delivered as 4–8 weekly sessions; brief (4 sessions), digital (Sleepio, SHUTi, Somryst-prescription digital therapeutic), and group formats are validated alternatives.
Five evidence-based components of CBT-I
1. Sleep restriction therapy (SRT)
The most powerful single CBT-I component. Restrict time in bed (TIB) to match average self-reported total sleep time (TST) from the baseline diary, with a floor of 5–5.5 hours. This induces mild sleep deprivation that consolidates the homeostatic drive and improves sleep efficiency (TST/TIB). Once efficiency reaches ≥85% over 5–7 days, increase TIB by 15–30 minutes weekly. Target sleep efficiency: ≥85%. Caution: contraindicated in bipolar disorder (risk of mania), seizure disorder (lowered threshold), in patients with parasomnias, and untreated OSA.
2. Stimulus control therapy
Re-establishes the bed/sleep association. Rules:
- Use the bed only for sleep and sex.
- Go to bed only when sleepy.
- If unable to fall asleep within ~20 minutes, leave the bed, engage in a quiet activity in dim light, and return only when sleepy. Repeat as needed.
- Wake at the same time every day, regardless of total sleep time.
- No daytime naps (or ≤30 min before 3 pm only if essential).
3. Sleep hygiene education
Standalone sleep hygiene is INSUFFICIENT for insomnia disorder treatment but is a routine adjunct: limit caffeine after noon, avoid alcohol within 3–4 hours of bed, limit nicotine, exercise regularly but not within 3 hours of bedtime, dark/quiet/cool bedroom, no screens within 1 hour of bedtime, no clock watching.
4. Cognitive restructuring
Identify and challenge maladaptive sleep beliefs: “If clinicians don’t get 8 hours, clinicians will be a wreck tomorrow.” “I must sleep — sleep is critical.” Replace with realistic, flexible beliefs. Address the sleep-effort paradox — trying harder to sleep activates wake systems and worsens insomnia.
5. Relaxation techniques
Progressive muscle relaxation, diaphragmatic breathing, body scan, paradoxical intention (try to stay awake), guided imagery, mindfulness-based stress reduction. Particularly helpful for patients with prominent somatic and cognitive arousal.
✓ Pearl
Digital CBT-I (Sleepio, SHUTi, Somryst) — the FDA-cleared prescription digital therapeutic — has demonstrated efficacy comparable to in-person CBT-I in multiple RCTs. When trained therapists are unavailable, recommend a validated digital program. Insurance coverage is rapidly expanding for these tools as awareness of CBT-I as first-line grows.
✗ Pitfall
Do NOT recommend “sleep hygiene only” as standalone treatment. Multiple RCTs and meta-analyses confirm that sleep hygiene alone has minimal efficacy in chronic insomnia disorder — it underperforms not only CBT-I but most active comparators. Sleep hygiene is a foundation, not a treatment.
4. Pharmacotherapy Hierarchy
The 2024 modern hierarchy for insomnia pharmacotherapy reflects evolving evidence on safety, abuse potential, residual sedation, dependence, and sleep architecture preservation. Choose by sleep complaint pattern (sleep-onset vs sleep-maintenance vs early-morning), age, comorbidities, and avoidance of contraindicated agents.
| Class / Drug | Standard dose | Best for | Notable cautions |
|---|---|---|---|
| DORAs (preferred new first-line) | |||
| Daridorexant (Quviviq) | 25–50 mg HS | Sleep onset + maintenance; minimal next-morning residual | Half-life ~8 h; CYP3A4 substrate; avoid potent CYP3A4 inhibitors |
| Lemborexant (Dayvigo) | 5–10 mg HS | Sleep onset + maintenance; faster onset than suvorexant | Avoid concurrent strong CYP3A4 inhibitors |
| Suvorexant (Belsomra) | 10–20 mg HS | Sleep maintenance; first-in-class DORA | Half-life ~12 h; next-day driving caution; narcolepsy contraindication |
| Z-drugs (second-line) | |||
| Zolpidem IR (Ambien) | 5–10 mg HS (women 5 mg) | Sleep-onset insomnia | Complex sleep behaviors (sleep-driving, sleep-eating); FDA black-box; women metabolize slower |
| Zolpidem CR (Ambien CR) | 6.25–12.5 mg HS | Sleep-onset + maintenance | Same complex behavior risk; longer next-morning impairment |
| Eszopiclone (Lunesta) | 1–3 mg HS | Sleep maintenance; longer half-life ~6 h | Bitter dysgeusia common; next-day residual |
| Zaleplon (Sonata) | 5–10 mg HS or middle of night ≥4 h before rising | Sleep onset; very short t½ ~1 h | Limited maintenance benefit |
| Sedating antidepressants (off-label) | |||
| Trazodone | 25–100 mg HS | Insomnia with depression or anxiety | Orthostatic hypotension, priapism (rare); not FDA-approved for insomnia alone |
| Doxepin (Silenor) | 3–6 mg HS | Sleep maintenance, older adults; FDA-approved for insomnia | Anticholinergic at higher doses; avoid in narrow-angle glaucoma, urinary retention |
| Mirtazapine | 7.5–15 mg HS | Insomnia with depression and weight loss | Weight gain, daytime sedation, restless legs |
| Melatonin / Melatonin agonists | |||
| Melatonin (OTC) | 0.5–3 mg HS (small dose better) | Circadian disorders, jet lag; modest benefit in insomnia | OTC quality varies dramatically; useful in older adults |
| Ramelteon (Rozerem) | 8 mg HS | Sleep-onset insomnia; no abuse potential | Modest effect; avoid with fluvoxamine (CYP1A2) |
| AVOID — outdated/risky | |||
| Benzodiazepines (alprazolam, diazepam, temazepam, lorazepam) | — | Avoid for chronic insomnia | Tolerance, dependence, withdrawal; CNS depression with opioids; falls/fractures in elderly; cognitive impairment |
| Diphenhydramine, doxylamine (OTC) | — | Avoid in older adults (Beers Criteria) | Anticholinergic burden, delirium risk, urinary retention, falls; tachyphylaxis within days |
| Quetiapine for insomnia (no psychiatric indication) | — | Avoid as first-line hypnotic | Metabolic syndrome, weight gain, EPS, QTc; off-label use without indication is increasingly discouraged |
Why DORAs are preferred
Dual orexin receptor antagonists block both OX1R and OX2R receptors of orexin (hypocretin) — the wake-promoting neuropeptide system overactive in insomnia. By dampening wake drive rather than enhancing GABA-A inhibition (the mechanism of benzodiazepines and Z-drugs), DORAs preserve sleep architecture, do not cause anterograde amnesia, do not produce complex sleep behaviors, have negligible abuse potential, and minimize next-morning residual sedation. DORAs are also less likely to suppress REM sleep or cause rebound insomnia on discontinuation. Major remaining caveats: cost (limited formulary coverage in some health systems), rare next-morning impairment with longer-half-life agents (suvorexant), and contraindication in narcolepsy.
Z-drugs — appropriate use and the FDA black box
Z-drugs (zolpidem, eszopiclone, zaleplon) bind selectively to α1-containing GABA-A receptors and remain widely used. The 2019 FDA black-box warning highlights complex sleep behaviors — sleep-driving, sleep-eating, sleep-walking, and engaging in other activities while not fully awake — particularly with zolpidem. Discontinue Z-drug if such events occur. Use shortest effective duration; reassess at 2–4 weeks; combine with CBT-I.
Sedating antidepressants — niche role
Trazodone at low dose (25–100 mg) is widely prescribed off-label and is appropriate when insomnia coexists with depression. Doxepin at very low doses (3–6 mg) is FDA-approved for sleep maintenance and is well tolerated in older adults despite its tricyclic class. Mirtazapine is useful for the depression-insomnia-anorexia triad. Avoid using sedating antidepressants alone for primary insomnia without comorbid depression.
5. Special Populations & Tapering
Special populations
| Population | Approach |
|---|---|
| Older adults (≥65 yr) | CBT-I first-line; if pharmacotherapy needed, prefer doxepin 3–6 mg, low-dose DORAs, or melatonin; AVOID diphenhydramine (Beers), benzodiazepines, Z-drugs in fall-risk patients |
| Pregnancy | CBT-I first-line; non-pharmacologic only when possible. If essential, low-dose doxepin, very-short-course diphenhydramine (FDA pregnancy class B but anticholinergic), or sleep-positioning. Avoid Z-drugs in 1st trimester |
| Insomnia with depression | SSRI/SNRI for depression + CBT-I; trazodone 25–100 mg HS adjunct; mirtazapine if weight loss |
| Insomnia with PTSD | CBT-I + imagery rehearsal therapy (IRT) for nightmares; prazosin 1–6 mg HS for nightmares; avoid benzodiazepines (worsen PTSD) |
| Insomnia with chronic pain | Treat pain; CBT-I; doxepin or trazodone HS adjunct; avoid chronic opioids for sleep |
| OSA with insomnia (COMISA) | Treat OSA with CPAP first; many insomnia symptoms improve; remaining insomnia → CBT-I |
| Renal/hepatic impairment | Reduce hypnotic doses; avoid Z-drugs in severe hepatic impairment; DORAs require dose reduction with strong CYP3A4 inhibitors |
| Shift workers | Strategic napping, light therapy, melatonin timing, modafinil for excessive sleepiness; treat as circadian rhythm disorder |
Tapering hypnotics — structured discontinuation
After CBT-I has been delivered and sleep has stabilized, plan a gradual taper of any hypnotic. Abrupt discontinuation produces rebound insomnia in 30–50% of patients and risks withdrawal in those on benzodiazepines or chronic Z-drugs.
- Z-drugs and DORAs: 25% dose reduction every 1–2 weeks. Pair with continued CBT-I session focusing on cognitive restructuring around medication dependence.
- Benzodiazepines: convert to long-acting equivalent (e.g., diazepam) and taper by 10–25% every 1–2 weeks; longer tapers (months) for high-dose or long-duration users.
- Trazodone, doxepin: small reductions every 2–4 weeks; minimal withdrawal at low hypnotic doses.
- Melatonin: simply discontinue; no taper required.
6. Frequently Asked Questions
Why is CBT-clinicians considered first-line over medication?
Should I prescribe DORAs (suvorexant, lemborexant, daridorexant) over zolpidem?
Is melatonin actually effective for insomnia?
When should clinicians avoid prescribing diphenhydramine for sleep?
How do I taper a patient off long-term zolpidem or benzodiazepines?
S7. Practice Insights: Insomnia Management Beyond Z-Drugs and Trazodone
1. CBT-I as Default First-Line
In practice, every chronic insomnia patient (insomnia disorder per DSM-5-TR criteria, >3 nights/week for >3 months) starts with cognitive behavioral therapy for insomnia (CBT-I) rather than medication. CBT-I components include: sleep restriction (matching time-in-bed to actual sleep time, then gradually increasing), stimulus control (bed only for sleep and sex, get up if not asleep within 20 minutes), sleep hygiene (consistent wake time, no naps, no caffeine after noon, no screens 1 hour before bed), cognitive restructuring (challenging catastrophic thoughts about sleep loss). Access barriers (limited sleep psychologist availability) are increasingly solved by digital CBT-I platforms (Sleepio, Somryst, SHUTi) which have FDA clearance and good real-world data. Long-term outcomes from CBT-I exceed any pharmacotherapy.
2. DORAs as Preferred Pharmacotherapy
In experienced hands, when pharmacotherapy is needed, dual orexin receptor antagonists (DORAs) are the first-line: suvorexant 10-20 mg, lemborexant 5-10 mg, or daridorexant 25-50 mg. The orexin neuropeptide system promotes wakefulness; antagonizing it allows physiologic sleep. DORAs have substantially better safety profile than benzodiazepines or Z-drugs: no GABAergic dependence/tolerance, less next-day sedation, less cognitive impairment, no association with falls in elderly (vs benzo/Z-drug 2-3x fall risk), no respiratory depression. Cost is the main barrier ($300-500/month without insurance coverage), and insurance authorization often requires documented failure of CBT-I or other agents. Side effects: nightmares (less common than predicted from REM-related mechanism), morning grogginess in some patients (more with suvorexant than lemborexant or daridorexant).
3. Avoid Benzos and Z-Drugs as Default
In experienced practice, benzodiazepines (temazepam, lorazepam) and Z-drugs (zolpidem, eszopiclone, zaleplon) are NOT first-line and used only for short-term (<2-4 weeks) or as bridge therapy while CBT-I is initiated. Their harms include: dependence and rebound insomnia on discontinuation, next-day sedation and cognitive impairment, falls in elderly (~2-3x risk), motor vehicle crash risk, parasomnias (sleep-driving, sleep-eating with zolpidem), and the AGS Beers Criteria lists them as inappropriate for older adults. Long-term use is associated with cognitive decline and increased dementia risk in observational studies. When clinicians inherit a patient on chronic Z-drug or benzo therapy, experienced clinicians taper with patient buy-in over weeks-months, often transitioning to CBT-I and/or DORA bridging.
4. Trazodone Is Overprescribed
Trazodone is widely prescribed off-label for insomnia at low doses (50-100 mg), but the evidence base is weak and the side-effect profile is meaningful. In experienced practice clinicians have largely moved away from trazodone for insomnia given: orthostatic hypotension with associated fall risk in elderly, priapism risk in men (rare but irreversible if not treated promptly), anticholinergic burden adding to cognitive concerns, daytime sedation hangover. Trazodone retains a role as adjunct in patients with depression where the antidepressant effect is also wanted, but using it solely for insomnia in the absence of mood disorder is rarely the preferred approach now. Other sedating antidepressants (mirtazapine, doxepin 3-6 mg) and antipsychotics (quetiapine off-label) are similarly problematic — used for sedating side effect rather than therapeutic indication.
Illustrative Scenario: Z-Drug Taper Plus CBT-I Plus DORA Bridging
An elderly woman with 12 years of nightly zolpidem 10 mg use presented requesting “the next strongest sleeping pill” because zolpidem was no longer working. Detailed history revealed she was having nightly arousals 2-3 times, taking 60-90 minutes to fall asleep, and was experiencing morning cognitive fog and three falls in the prior 18 months. Z-drug tolerance plus rebound effect was driving the cycle.
The treating clinicians framed the path as zolpidem taper plus CBT-I plus temporary DORA bridging. She was referred to digital CBT-I (Somryst) and started lemborexant 5 mg nightly. Zolpidem was tapered by 1.25 mg every 2 weeks. The taper was uncomfortable initially with rebound insomnia in weeks 2-4 but she persisted with daily CBT-I exercises. By month 4 she was off zolpidem entirely, on lemborexant 5 mg nightly with adequate sleep, no daytime fog, no falls. By month 8 she successfully discontinued lemborexant and was managing on CBT-I behavioral changes alone. Falls did not recur in the 18 months of follow-up after completing taper.
Practice Pattern Refinements vs Standard Approach
- CBT-I as first-line for chronic insomnia disorder (AASM 2021). Digital CBT-I (Sleepio, Somryst, SHUTi) solves access. Long-term outcomes exceed any pharmacotherapy.
- DORAs (suvorexant/lemborexant/daridorexant) as preferred pharmacotherapy: no GABA dependence, less next-day sedation, no fall risk in elderly. Cost is barrier.
- Avoid benzos and Z-drugs as default: only short-term (<2-4 wk) or bridge therapy. Beers Criteria inappropriate for elderly. Falls, cognitive impairment, parasomnia.
- Move away from trazodone for insomnia alone: orthostasis, priapism, anticholinergic burden. Retain only as adjunct in mood disorder where antidepressant effect wanted.
- Narcolepsy Type 1 and Type 2: Diagnosis with MSLT, Hypocretin Deficiency, and Modern Pharmacotherapy
- Circadian Rhythm Sleep-Wake Disorders: DSPD, ASPD, N24, Shift Work, and Jet Lag Management
- Acute Diverticulitis: Hinchey Staging, Antibiotic Selection, and Indications for Surgical Intervention
- REM Sleep Behavior Disorder: Diagnosis, Polysomnography, and Neurodegenerative Risk
- Cellulitis: Diagnosis, Antibiotic Selection, and Management
- Hypertension — Diagnosis, Risk Stratification, and Pharmacotherapy